In the study conducted by Holz et al. (9) to evaluate the real-life data of anti-VEGF treatment in many countries in exudative AMD, the number of visits of the patients was found as an average of 8.6 in the 1st year and 6.4 in the 2nd year, and the number of injections was found average of 5.0 in the 1st year and 2.2 in the 2nd year. This evidence concerns the gene VEGFA and age-related macular degeneration.